Ginkgo Bioworks Holdings Inc Stock Falls 7.48%, Earns Bearish Rating from InvestorsObserver Sentiment Indicator.
March 4, 2023
Trending News 🌥️
InvestorsObserver Sentiment Indicator has given Ginkgo Bioworks ($NYSE:DNA) Holdings Inc a Bearish rating after the stock has dropped 7.48% over the past week. Ginkgo Bioworks Holdings Inc is a biotechnology company that is focused on developing and commercializing solutions in the field of synthetic biology. This suggests that investors are losing confidence in the company and its stock as it does not seem to be maintaining its previous popularity and performance. This could be due to a variety of factors, including the news last month that Ginkgo Bioworks Holdings Inc would be acquiring Zymergen, a synthetic biology platform.
Investors may be concerned about how the acquisition will affect Ginkgo Bioworks Holdings Inc’s financials or the company’s overall future. This drop may be a sign that investors are losing confidence in the company, which could indicate that Ginkgo Bioworks Holdings Inc’s stock performance may be volatile in the future. It will be interesting to see how this situation develops over time and if Ginkgo Bioworks Holdings Inc can turn things around and regain investor confidence.
Market Price
Despite the news, the current news coverage remains mostly positive with the company having a bright outlook among analysts and investors. This has been driven by their innovative work in the biotech industry, with the company leading the way on a number of groundbreaking technologies. Despite this, the share price dropped significantly on Friday, suggesting that the stock may be facing some challenges in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ginkgo Bioworks. More…
| Total Revenues | Net Income | Net Margin |
| 477.71 | -2.1k | -462.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ginkgo Bioworks. More…
| Operations | Investing | Financing |
| -252.2 | -67.39 | 95.34 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ginkgo Bioworks. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.54k | 803.04 | 0.85 |
Key Ratios Snapshot
Some of the financial key ratios for Ginkgo Bioworks are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 106.6% | – | -444.1% |
| FCF Margin | ROE | ROA |
| -63.7% | -83.6% | -52.2% |
Analysis
At GoodWhale, we think it’s important for investors to understand the risks associated with any investment, especially as it pertains to the financials. That’s why we provide comprehensive financial risk analysis for each company we cover. One such company is GINKGO BIOWORKS, an organism design company that harnesses the power of biosystems engineering to design products from the microbial level up. After evaluating their financials alongside our Risk Rating, we rate GINKGO BIOWORKS as a medium risk investment in terms of financial and business aspects. Of course, no investment is without risk, and GoodWhale has identified one risk warning in GINKGO BIOWORKS’ financial journal. If you’re interested in learning more about the risks associated with investing in GINKGO BIOWORKS, please register on GoodWhale.com today. We’ll be happy to provide more detailed assessment of the company’s financial position and potential risks. More…
Peers
The competition among Ginkgo Bioworks Holdings Inc and its competitors is fierce. Abivax SA, Atreca Inc, and Kiromic BioPharma Inc are all vying for a piece of the pie in the biotechnology industry. Ginkgo Bioworks Holdings Inc has a strong hold on the market, but its competitors are quickly catching up.
– Abivax SA ($OTCPK:AAVXF)
Abivax SA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies with the potential to transform the lives of patients suffering from chronic inflammatory diseases and cancer. The Company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
Abivax SA has a market cap of 178.76M as of 2022, a Return on Equity of -132.3%. The company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
– Atreca Inc ($NASDAQ:BCEL)
Atreca Inc is a biopharmaceutical company that focuses on the development of antibody-based therapeutics to treat cancer. As of 2022, its market cap is 59.43 million and its ROE is -86.67%. The company’s focus on developing cancer treatments makes it a risky investment, but its potential rewards are high.
– Kiromic BioPharma Inc ($NASDAQ:KRBP)
Kiromic BioPharma Inc is a clinical stage biopharmaceutical company that uses proprietary gene editing platform to develop cancer therapies. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Kiromic has a market cap of 5.32M as of 2022 and a Return on Equity of -127.9%. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Summary
Ginkgo Bioworks, the leading synthetic biology platform, recently saw its shares decline 7.48%. This bearish sentiment was reflected in investorsObserver’s sentiment indicator rating, which assigns a negative outlook for the stock. Despite this decline, overall news coverage for Ginkgo Bioworks has been largely positive as the company continues to profit from its groundbreaking solutions in the field of biotechnology. Analysts have pointed to Ginkgo’s recent successes as reasons to believe that the company can continue to grow and maintain its reputation as a leader in the industry.
Market watchers have also suggested that investors may be able to benefit from Ginkgo Bioworks’ strong potential for future profits. While there may be risks involved in investing, the overall outlook for Ginkgo Bioworks appears to remain positive.
